Capital constraints, evolving patient expectations and smaller teams are making clinical trials harder to run. Organizations advancing drugs through trials now operate in a more complex, less standardized environment. They are managing tighter budgets and leaner teams while making faster, high-stakes decisions.

At the same time, trial designs are becoming more adaptive and global, with artificial intelligence (AI) helping to predict enrollment trends and trial outcomes. Decentralized or hybrid models are becoming more prevalent, distributing responsibilities across more sites, partners and systems. While these approaches can improve access and generalizability, they also increase coordination demands across supply, data and patient engagement. Additionally, they introduce potential new risks, like technology failures and data integrity concerns. Addressing these threats requires integrated platforms and monitoring plans that offer flexibility to prevent downstream deviations or delays that require corrective actions.

In today’s landscape, variability in trial design is no longer an exception. It is built into how trials are shaped and executed. This shift is changing what biotechs need from their partners. For this reason, strategic collaboration with integrated CDMOs/CROs is becoming more important for execution and early input. Considering manufacturing, packaging and distribution earlier allows teams to anticipate risks before protocols lock them in. Because of these factors, clinical supply is becoming a central lever for managing complexity, enabling more flexible study models and determining how effectively sponsors can navigate the growing number of moving parts in this modern environment. 

From ship-to-site to patient-ready supply

Clinical supply must align with trial design. Traditional site-based shipping struggles with uneven enrollment, mid-study country additions or remote participation. In more flexible models, supply flows must reflect patient pathways and enrollment patterns rather than forcing rigid protocols. 

Direct-to-patient distribution is one example of a decentralized and patient-centric clinical trial supply model, but it only works when custody, temperature control and documentation standards are built into the process from the start. Models like pharmacy-to-patient or depot-to-patient offer different advantages depending on the requirements of a specific trial. The pharmacy-to-patient model allows for patient-specific dosing and coordination with pharmacists or other home health providers. These factors make this model well suited for more complex populations. Alternatively, depot-to-patient models can support more standardized supply needs. Traditional site-based delivery remains the most widely used and cost-effective model. Deciding the right approach is an important choice that will ultimately impact operational complexity, as well as patient experience.

 Integration with interactive response technology (IRT) systems has also become essential, since real-time dosing logic and inventory visibility are critical when supply needs shift quickly. Structured reforecasting and change management are equally important when enrollment changes from the original plan, which is increasingly common in global trials.

Packaging and labeling as strategic levers

Packaging and labeling are often treated as a final step before first patient dosing. But they are critical, shaping how the drug is stored, distributed and used. The decisions also help ensure compliance, traceability and safety. When sponsors determine packaging and labeling solutions after the trial has already been designed, it becomes difficult to adjust as trial parameters change.

Four factors are critical to effective clinical supply execution:

• Speed determines how quickly studies can kick off, especially when translation and approvals are on the critical path. 
• Reliability and risk mitigation protect against issues like tampering, temperature excursions or labeling errors that can interrupt supply. 
• Flexibility becomes critical when protocols change, helping teams avoid waste and rework. 
• Cost efficiency improves when these elements are aligned upfront, rather than managed after problems emerge.

A more resilient approach incorporates a packaging strategy early in trial planning and aligns it with dose design and site selection. Earlier packaging and labeling decisions help maintain regulatory compliance, protect product integrity and reduce delays. Integrated CDMOs/CROs have access to expertise and technology that sponsors often don’t, making it easier to anticipate downstream constraints.

Several operational strategies can support this approach, including just-in-time labeling when regulations allow. Late-stage packaging strategies avoid peak-demand bottlenecks and smart label design with multilingual booklet labels for global trials. Early fit and stress testing for device kits or cold-chain configurations can also prevent disruptions later in the study.

Workflow improvements demonstrate the impact. In one example, a CDMO reduced labeling translation timelines by up to 70%. Changes like this can accelerate study startup timelines by weeks or even months.

Technology and data-driven planning

Data-driven planning also helps to close the gap between trial assumption and actual execution. Forecasting and scenario modeling helps teams evaluate demand shifts, site additions and enrollment variability before they happen. Digital workflows reduce manual work in batch records and label approvals, while flexible manufacturing lines enable rapid changeovers for small-batch production. These capabilities allow teams to respond to change right when it happens. This can reduce delays, minimize risks, and keep trials on track as conditions change and evolve. 

Industry analysis underscores the growing role of predictive analytics and AI in guiding operational decisions. These tools help teams anticipate enrollment trends and adjust supply strategies earlier. Their value depends on modern systems and coordinated data architectures that keep clinical, manufacturing and supply teams aligned. For many sponsors, that shift requires partnering with CDMOs that already have these integrated capabilities in place, enabling faster adoption without building the infrastructure from scratch.

For example, a sponsor applied a CDMO’s simulation tools across three studies spanning two continents, 585 sites and more than 2,000 patients to test and refine supply strategies. The collaboration optimized inventory and distribution planning, reducing bulk drug product by 54% (about €1.5 million in savings) and lowering site burden for managing investigational medications. This highlights the value of strategic partnership between sponsors and CDMO/CROs. At the end of the day, these savings can help translate to better patient outcomes. 

Preparing for trial operations moving forward

Preparing trial operations requires moving beyond traditional handoff models. Biotechs benefit from working alongside clinical operations, supply and quality teams earlier in planning. This allows risks to be addressed before timelines solidify. A single end-to-end plan linking enrollment to manufacturing, packaging, shipping and resupply helps prevent fragmented responses when protocols change.

The takeaway is straightforward. As trials become more adaptive and global, success depends on integrated operational planning. Sponsors that break down silos and collaborate with experienced CDMO/CRO partners will be better positioned to deliver flexible trials without sacrificing speed, quality or cost.

Luke Wilson is Senior Director of Commercial Operations and Global Biotech Leader for the Clinical Trials Division at Thermo Fisher Scientific. He leads global biotech commercial strategy, partnering with biotech and pharmaceutical companies to deliver innovative, patient-centric clinical trial solutions, including decentralized and hybrid trial models. With more than ten years of experience across clinical supply chain, Luke brings deep expertise in enabling scalable, technology-driven clinical trials worldwide.

Amanda Bosse has more than 20 years of strategic and organizational leadership experience across pharmaceutical services from early-stage clinical development through commercial manufacturing and lifecycle management. She currently serves as President, Clinical Trials at Thermo Fisher Scientific, where she leads an innovation driven portfolio of services supporting biopharma and biotech customers across the clinical development supply chain, enabling new therapies to reach the market faster.